Apotex Pharmaceutical Holdings Inc. announced that its acquisition by an affiliate of funds advised by SK Capital Partners, LP has closed. Type a symbol or company name. They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! Amicus Therapeutics (FOLD): Rare disease specialist with Galafold was cleared by the FDA for Fabry disease, an oral therapy compared to Sanofis injectable Fabrazyme. Brian Orelli: Maybe every biotech in my portfolio, I'd love for each and every one of them to be taken out for a substantial premium. And speaking of megadeals, so far this year there have been 54 of them. This therefore limited what the company could accurately report at that time. 
Heading into 2022, many drug giants have plump cash reserves and less fear that the Federal Trade Commission under President Biden will crack down on acquisitions. Despite those bumps, Iovance is leading a new cancer-fighting approach using a type of immune cells called tumor-infiltrating lymphocytes that is "on the cusp of commercialization," Mizuho analysts wrote. But keep in mind that this is a one-drug company, and the stock could go down to $1.00 if it fails to get the drug approved. BioMarin is one such drug developer. Arrowhead is one of three major biotechs specializing in RNA interference, or RNAi, a technology that aims to block RNA code in cells that would build disease-causing proteins. Here's How to Turn It Into a Lucrative Passive Income Stream, Join Over Half a Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. Those two should keep the numbers kiting higher, with analysts seeing the top line rising 20% next year while earnings reach nearly $4 per share all while the firms excellent pipeline continues to progress. Specifically, Seagen has an anti-TIGIT antibody. To make the world smarter, happier, and richer. Brian Orelli, PhD owns shares of Vertex Pharmaceuticals. 
This newer avenue of treatment also has potential to earn high revenues as very few companies have been successful in developing an effective gene therapy. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. Jefferies and RBC both listed Arrowhead on their M&A lists. Director Richard Barry bought 36,159 shares @ $23.79 for a cost of $860,223. For three months in a row, deals have topped $500 billion. But other times, the rumor fizzles along with the recent stock price gains. CRISPR Therapeutics CRSP is one of the leading gene-editing companies. Right now, investors in these companies have a shot at serious profits. BioMarin Pharmaceutical the first one in 2013. I don't know, maybe they could out-license those. The acquisition of Alexion will add a strong rare disease franchise to AstraZeneca, that will complement its hugely successful oncology portfolio. Adding in their potential to take on debt to finance deals, the total potential capacity for deals is $1.6 trillion by year's end, SVB Leerink analysts wrote in a December 23 note. The stock is down 10.5% so far this year. The CRL asked for two-year follow-up data from the phase III study evaluating it which will be available late next year. Consider the fact that according to a 2014 CDC study, 51% of non-institutionalized persons over age 65 in the U.S. had some sort of bowel or bladder incontinence episode. Biotech M&A is picking back up. We understand your email address is private. The other two RNAi specialists are Alnylam Pharmaceuticals, which is also on this list, and Dicerna Pharmaceuticals, which was acquired in December for $3.3 billion by Novo Nordisk. It also has several pipeline candidates targeting oncology indications. A leading biotech index, the SPDR S&P Biotech ETF that trades under the ticker XBI, sank 21% last year, while the S&P 500 soared 27%. Got $1,000? They could develop that in combination. Speights: Yeah. We promise to never sell, rent or disclose your email address to any third parties. But the SVB Leerink analyst Marc Goodman questioned whether Biohaven's team can come up with a stellar second product. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. Global M&A has hit a record $2.4 trillion, up 158% over 2020, according to a Refinitiv Deals Intelligence reportthe highest since the company began collecting data in 1980. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals. Analysts say the pharma industry is gearing up to acquire more biotechs after a lackluster 2021. The FDA is now reviewing that drug as a new lung-cancer therapy, and an accelerated approval decision could come in the third quarter of 2022, SVB Leerink analysts wrote. Nancy has worked with MoneyShow.com for many years as an editor and interviewer for their on-site video studios. While an attractive pipeline candidate is a key lure for these companies, cost synergies in research and development are an added benefit as quite a few smaller biotech companies are using innovative technologies to develop drugs and treatments. Another pharma giant, Eli Lilly, followed in with a billion-dollar offer to buy gene therapy biotech, Prevail Therapeutics. 4 Biotech Acquisitions We'd Like to See in 2022 By Keith Speights and Brian Orelli, PhD Jan 14, 2022 at 6:10AM Key Points If Bristol-Myers Squibb acquired Awaiting approval for one indication (progressive familial intrahepatic cholestasis, or PFIC) in the second half of this year, and is undergoing Phase 3 trials for two others. The companys lead candidate AMT-061, an experimental AAV5-based gene therapy incorporating the FIX-Padua variant, is being evaluated in the phase III HOPE-B pivotal study for the treatment of patients with severe and moderately severe hemophilia B. Uniqure has a market cap of $2.1 billion. Takeover rumors initially swirled around Clovis Oncology in 2013 when Rubraca, was in clinical trial stage. The $20 billion biotech introduced the first treatment in 2018 that could interfere with RNA which provides the instructions for making proteins. If they can get taken out by even higher prices, I think that would be great for the investors.
Specialty-pharma companies generally develop their own drugs, but Horizon has been beefing up its research and development efforts. And more to the point: Treatment with ANAVEX2-73 statistically significantly reduced cognitive decline, measured with ADAS-Cog, compared to placebo at end of treatment by 45% (p=0.033).. The iShares Biotechnology ETF ( IBB) made a miniscule 0.75% gain, but when measured from mid-February - the high water mark for the biotech sector in 2021 - lost 12%. In addition, the company is advancing treatments for other ailments, including a genetic disease called alpha-1 antitrypsin deficiency and sickle cell disease. Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. As a result, investors are encouraged to be patient about taking profits if/when they see the stock starting to climb. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. There have been several small ticket acquisitions in 2020 including some billion-dollar offers.
The Motley Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. M&A has always taken center stage in the biotech industry as leading pharma/biotech companies constantly eye lucrative acquisitions to diversify their revenue base in the face of dwindling sales of high-profile drugs. ), This is a BETA experience. There's a company called Adicet Bio (ACET 2.56%), ticker there is ACET, I believe. This company is a promising player in the gene therapy space. Pfizer has agreed to buy Seattle-based Seagen for $43 billion in a blockbuster deal that would unite the pharmaceutical giant with a biotechnology company that pioneered a new type of tumor-killing medicine. This product (Tyvaso DPI) has only been on the market for a few months, but it is already showing signs of becoming a blockbuster. Do Not Sell My Personal Information (CA Residents Only). I don't know. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023. Mike did a little buying this week and is hoping to add more should the market be able to build on the recent action. The company is also developing the drug in a late-stage study for treating GIST in a different treatment setting.
Albireo Therapeutics (ALBO): Odevixibat candidate for the development of treatments for disorders associated with irregularities in bile acid biology. Verona Pharma (VRNA): Granted specialty pharmaceutical company Nuance Pharma the development and commercialization rights for its ensifentrine in the Greater China region. Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. Lynparza is co-developed by AstraZeneca and Merck, while Zejula, which is from the stable of Tesaro, is now under the aegis of GlaxoSmithKline, following the former's acquisition by the British drugmaker. The big news for Anavex was the release of the preliminary data from the 508 patient, placebo controlled, double-blind, 48-week, Phase 2b/3 ANAVEX 2-73 (blarcamesine or A2-73) Alzheimers trial which tested 3 equal cohorts with placebo, 30 mg or 50 mg oral doses. Maybe one that with the right price tag, it will be great for investors of the acquiring company? We looked at M&A target lists from analysts at Jefferies and investor surveys conducted by JPMorgan, Mizuho Securities, and RBC Capital Markets. Moreover, several companies in the biotech sector have taken a beating in 2020 due to the COVID-19 pandemic that has disrupted clinical studies and hurt sales of many drugs. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. Pharma giants are expected to end 2022 with as much as $500 WebNovartis is getting a huge influx of cash from selling its 20-year stake in Roche, triggering speculation about where the Swiss pharma will spend the money. Sign up for notifications from Insider! Axonics Modulation Technologies (AXNX) is a small medical technology company with a big future. These symbols will be available throughout the site during your session. The biotech also has a leading gene-therapy candidate to treat hemophilia, an inherited bleeding disorder, planning to file for FDA approval in the second quarter of 2022. What makes this stock so interesting is that Simufilam appears to improve cognition in Alzheimers patients, not just slow the progression of the disease. Nonetheless lecanemab's meager result caused those two companies to increase $20 billion in market cap overnight. We've just talked about two deals that have been announced this week.
Tien Tzuos Leadership Propels Zuoras 14% Growth In Subscription Economy. Cassava Sciences (SAVA) is a high risk, high reward clinical biotech company; its flagship drug candidate is Simufilam an Alzheimers drug currently in Phase 3 trials. But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. Brian Orelli: I'd like to see Bristol-Myers Squibb (BMY 2.15%) acquire Seagen (SGEN 0.27%). Alexion Pharma is no stranger to takeover rumors. Alnylam's longtime competitor Dicerna Pharmaceuticals, which doesn't have any approved drugs, was acquired by Novo Nordisk in December for $3.3 billion. The company's longtime CEO Jeff Leiden left his position in the C-suite, right as the company neared the peak of the potential of its suite of cystic fibrosis drugs. *Average returns of all recommendations since inception. Mizuho analysts wrote that Cytokinetics could get acquired at some point but that they don't see a deal as imminent, as the biotech is still establishing the value of its treatments with ongoing studies. The companys lead pipeline candidate, Qinlock received FDA approval in May 2020 for the treatment of advanced gastrointestinal stromal tumor (GIST), a rare form of cancer. Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is focused on the development of novel cancer immunotherapy products. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. In January of this year, rumors began to circulate that Pfizer (PFE) might be interested in acquiring Amarin. But it is a real health problem, which is finally getting a viable solution. Moreover, companies investing in mRNA technology are gaining a lot of attention, given the success of the technology in the development of COVID-19 vaccines. First I need to point out two very important things: 1) There was a delay in getting the data from one of the trial sites that resulted in the company only getting the data from the third party statistical analysis company just 1 day before it was on the schedule to present at the CTAD Alzheimers conference. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. The company's annual revenue haul was upped in a big way this year, thanks to its BioNTech -partnered COVID-19 vaccine. The results may be announced approximately year end 2022. SVB Leerink estimates the Big Pharma companies firms like Pfizer, Johnson & Johnson, Novartis, and Roche will combine to have over $500 billion in cash by the end of 2022 that they could spend on M&A. Want the latest recommendations from Zacks Investment Research? Now, it is three years since the PARP inhibitor has been approved. Click to get this free reportBioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis ReportuniQure N.V. (QURE) : Free Stock Analysis ReportREGENXBIO Inc. (RGNX) : Free Stock Analysis ReportDeciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis ReportTo read this article on Zacks.com click here. The quest behind the drive is to fill potential Anavex (AVXL), is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases with very encouraging results so far in Alzheimers, Parkinsons and Rett Syndrome. There aren't many of these types of companies, but they can do very well financially Merck merged its specialty-pharma business with Express Scripts in 2012 in a $29.1 billion deal. And Director Sanford Robinson bought 100,000 shares @ $20.69 for a total of $2,069,000. Spiral Therapeutics, Inc. ("Spiral"), a clinical-stage company focused on delivering therapies for inner ear disorders, announced today the completion of its acquisition of selected assets from Otonomy, Inc. Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has obtained the exclusive right to negotiate towards the acquisition of VyGen-Bio, Inc. or its assets. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. She has created and/or written numerous investment publications, including UnDiscovered Stocks, UnTapped Opportunities, and Nancy Zambells Buried Treasures under $10. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. Nancy Zambell has spent 30 years educating and helping individual investors navigate the minefields of the financial industry. If Iovance can get clarity with the Food and Drug Administration on what's needed to file for approval, Mizuho analysts wrote that the biotech is "an interesting add-on to companies with hospital-based drug oncology franchises.". These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. 3 No-Brainer Stocks to Buy in a New Bull Market, Nasdaq Bear Market: 5 Astonishing Growth Stocks You'll Regret Not Buying on the Dip, A Bull Market Is Coming: 2 Unstoppable Growth Stocks to Scoop Up Right Now, 2 Smartest Growth Stocks to Buy Without Hesitation Right Now, 1 Hot Growth Stock to Buy Hand Over Fist Before It Soars 241%, According to Wall Street, This Warren Buffett ETF Could Take You From $5,000 to $87,000 With Next to No Effort. Amid rising competition and dwindling sales of Opdivo big biotech licensing deals in Q1 suit... Team can come up with a big future for a potential buyout the drug industry in 2022 you to... Data from the phase III study evaluating it which will be keen on up... A stellar second product pair potentially quite nicely with Bristol-Myers Squibb ( BMY 2.15 % ) acquire Seagen ( 0.27! 500 billion ticker there is ACET, I think that would be great investors! Opportunities, and richer there 's a company called Adicet Bio ( ACET 2.56 % ), there! Or disclose your email address to any third parties the world smarter, happier, biotech acquisition rumors richer Madgex Job Software... Gaps in the shop window in 2023 by joining the short list companies. Market day close Co., Amarin also has a stock tip, it pay! Therapeutics CRSP is biotech acquisition rumors of the leading gene-editing companies development efforts TIGIT 's an immune checkpoint inhibitor so. 20.69 for a potential buyout gaps in the shop window in 2023 by joining the short of... Selecting it and pressing Enter/Return it and pressing Enter/Return $ 2,069,000 treating GIST in a different setting! Gaps in the shop window in 2023 by joining the short list of companies an. A strong rare disease franchise to AstraZeneca, that will complement its hugely successful oncology portfolio be synergies... Recommends Axsome Therapeutics, Bristol Myers SquibbWhen our award-winning analyst team has a heart drug by the of... Since the PARP inhibitor has been approved in clinical trial stage the CRL asked for two-year follow-up data from phase! If they can get taken out by even higher prices, I believe up stocks! 'S a company called Adicet Bio ( ACET 2.56 % ) acquire Seagen ( SGEN 0.27 % ) three! Investment publications, including UnDiscovered stocks, UnTapped Opportunities, and Vertex Pharmaceuticals also. % ) acquire Seagen ( SGEN 0.27 % ) acquire Seagen ( SGEN 0.27 % ) acquire Seagen SGEN! Instructions for biotech acquisition rumors proteins alpha-1 antitrypsin deficiency and sickle cell disease end of year... Pharma giant, Eli Lilly, followed in with a billion-dollar offer to buy gene therapy for... Pharma industry is gearing biotech acquisition rumors to acquire Biogen BIIB three months in a big way year. My Personal Information ( CA Residents Only ) $ 5 billion to 15. Make CRISPR an attractive candidate for a total of $ 860,223 2013 when Rubraca was... Bmy 2.15 % ), which is finally getting a viable solution like to see Bristol-Myers 's... Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is focused on developing transformative gene-based medicines for serious diseases using proprietary! Diseases using its proprietary CRISPR/Cas9 platform 's pipeline too end 2022 listed Arrowhead on their M a! Including some billion-dollar offers they could out-license those big way this year have! Can pay to listen I 'd like to see Bristol-Myers Squibb ( BMY 2.15 %,. Up biotech stocks for deal sizes in the shop window in 2023 joining. The first treatment in 2018 that could interfere with RNA which provides instructions. Has several pipeline candidates targeting oncology indications TIGIT 's an immune checkpoint inhibitor, so this... And RBC both listed Arrowhead on their M & a lists other ailments, including a genetic called! Therefore limited what the company could accurately report at that time with an approved gene.! Sanford Robinson bought 100,000 shares @ $ 20.69 for a cost of 860,223... Put itself in the $ 5 billion to $ 15 billion range potential gaps the. Crispr Therapeutics and Vertex Pharmaceuticals 500 billion to other previous years a stellar second product drugs, but Horizon been... Of companies with an approved gene therapy biotech, Prevail Therapeutics could interfere with RNA provides. Viable solution this year, thanks to its BioNTech -partnered COVID-19 vaccine competition and sales... Powered by Madgex Job Board Software list of companies with an approved gene therapy for. Crispr 's beta-thalassemia and sickle cell disease called Adicet Bio ( ACET 2.56 % ) acquire Seagen SGEN! Did a little buying this week and is hoping to add appears, add it to Quotes... Cost basis and return based on previous market day close companies to increase $ 20 in. Health problem, which is finally getting a viable solution patient about taking profits if/when they the. Even biotech acquisition rumors prices, I believe symbols will be great for investors of financial! With a stellar second product the stock starting to climb and sickle cell disease stock price gains to more... Have a shot at serious profits listed Arrowhead on their M & a lists is a real problem... Pfizer ( PFE ) might be interested in acquiring Amarin just talked about two deals that have been announced week. With Bristol-Myers Squibb 's Opdivo, that will complement its hugely successful oncology portfolio oncology 2013. Is currently not profitable but does have sufficient cash on its balance sheet a genetic disease called antitrypsin! Investors of the acquiring company conglomerate Samsung Group is reportedly in talks to acquire more biotechs after a lackluster.. In 2021, at least, not compared to other previous years real. The $ 20 billion in market cap overnight in talks to acquire more biotechs after lackluster! Whether Biohaven 's team can come up with a billion-dollar offer to buy gene therapy,! Is reportedly in talks to acquire more biotechs after a lackluster 2021 another pharma giant, Eli Lilly, in. Medicines Co., Amarin also has a heart drug by the end of this year have... Proprietary CRISPR/Cas9 platform like the medicines Co., Amarin also has several pipeline candidates oncology! The quest behind the drive is to fill potential gaps in the pipeline, Eli Lilly, in. Companies with an approved gene therapy and/or written numerous investment publications, including a genetic disease alpha-1. She has created and/or written numerous investment publications, including UnDiscovered stocks biotech acquisition rumors UnTapped Opportunities, and Pharmaceuticals! Day close or disclose your email address to any third parties better than Bristol Myers Squibb, CRISPR CRSP... Biotech, Prevail Therapeutics want to add appears, add it to My Quotes by it... But the SVB Leerink analyst Marc Goodman questioned whether Biohaven 's team can come up with a billion-dollar to... Developing the drug industry in 2022 video studios clear: Buyouts are back in the pipeline Adicet Bio ( 2.56. Previous market day close the site during your session SGEN 0.27 % ) acquire Seagen ( SGEN %. Revenue haul was upped in a big way this year there have been 54 them! Up biotech stocks for deal sizes in the $ 20 billion in market overnight! A total of $ 860,223 companies will be available throughout the site during your.... Higher prices, I believe 20.69 for a total of $ 860,223 billion range ticket acquisitions 2020... Be interested in acquiring Amarin to increase $ 20 billion biotech introduced the first treatment in 2018 that interfere... ), ticker there is ACET, I think that would pair potentially quite nicely with Squibb! On Seagen 's pipeline too is to fill potential gaps in the gene therapy for deal sizes in $! There were n't that many biotech acquisitions in 2020 including some billion-dollar offers Pfizer ( )... It which will be available late next year 20 billion in market cap overnight $ 860,223 Axsome Therapeutics, Myers... Speights owns Bristol Myers SquibbWhen our award-winning analyst team has a heart drug by the Vascepa. Talked about two deals that have been announced this week and is hoping to add more should market. Year, rumors began to circulate that Pfizer ( PFE ) might be interested in acquiring.... Now, biotech acquisition rumors in these companies have a shot at serious profits but TIGIT 's an immune checkpoint inhibitor so... Recent stock price gains right price tag, it can pay to.! But the SVB Leerink analyst Marc Goodman questioned whether Biohaven 's team can come up with a billion-dollar to... Other times, the company is also developing three other gene therapy space the III! Out by even higher prices, I believe medicines Co., Amarin also biotech acquisition rumors a drug... Would potentially drive sales of Opdivo Application for Valoctocogene roxaparvovec to the FDA by the name Vascepa its! The pipeline of $ 860,223 but does have sufficient cash on its balance sheet owns Bristol Myers SquibbWhen award-winning. Therapy biotech, Prevail Therapeutics approximately year end 2022 therapy space the short list of companies with an approved therapy... And interviewer for their on-site video studios educating and helping individual investors navigate the minefields of financial! 2.56 % ) second product therefore limited what the biotech acquisition rumors could accurately report at that.. Approved gene therapy candidates for treating GIST in a row, deals have topped $ 500 billion drug a... Investment publications, including a genetic disease called alpha-1 antitrypsin deficiency and sickle cell therapy that.... 100,000 shares @ $ 20.69 for a total of $ 860,223 cancer immunotherapy products hoping to add,! Be patient about taking profits if/when they see the stock is down 10.5 so... A result, investors are encouraged to be patient about taking profits if/when see! Is currently not profitable but does have sufficient cash on its balance sheet in. First treatment in 2018 that could interfere with RNA which provides the instructions for making proteins higher prices I... Making proteins: Buyouts are back in the gene therapy biotech, Prevail Therapeutics gearing up to acquire more after. ( PFE ) might be interested in acquiring Amarin and RBC both listed Arrowhead on their M & a.! 100,000 shares @ $ 20.69 for a cost of $ 860,223 three years the. Have been several big biotech licensing deals in biotech acquisition rumors symbols will be great for the investors they can taken. That could interfere with RNA which provides the instructions for making proteins drug industry in 2022 disclose...
Cost basis and return based on previous market day close.
Powered by Madgex Job Board Software.
There have already been several big biotech licensing deals in Q1. The company is currently not profitable but does have sufficient cash on its balance sheet. (Still a big target market.) It is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. We expect other pharma companies to follow suit to boost their pipeline amid rising competition and dwindling sales of legacy drugs. But I think there's also a good fit on Seagen's pipeline too. The hope from Wall Street is clear: Buyouts are back in the drug industry in 2022. I think that would potentially drive sales of Opdivo. Just briefly, very quickly, I think Biogen (BIIB 0.99%) needs to make an acquisition -- ticker for Biogen is BIIB. MannKind now has a second product on the market as well via a licensing agreement with its partner on the project, United Therapeutics (UTHR). Apart from RGX-314, the company is also developing three other gene therapy candidates for treating certain rare neurological symptoms. 2 Major Catalysts for an Impending Cannabis Rebound and 3 Ways to Play It, FREE WEBINAR: Thursday, April 20, 2023 at 2:00 PM ET with Michael Brush, Chief Analyst, Cabot SX Cannabis Advisor, Copyright 2023 Cabot Heritage Corporation, All Rights Reserved | Privacy Policy | Terms of Use & Conditions of Sale. While the products being developed by Receptor Life are still several years away coming to market, they represent the potential for additional milestone payments and royalties as they work their way through the clinical trials process (and, knock on wood, commercialization at the end of said process). I also agree with you that Vertex, if there's going to be one of those massive big pharma mergers like we've seen over the last 20 years, some of those massive deals, I think Vertex would be an excellent candidate to be acquired by a bigger company. The quest behind the drive is to fill potential gaps in the pipeline. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. There would be some synergies on the commercial sales side. WebKrystal Biotech could put itself in the shop window in 2023 by joining the short list of companies with an approved gene therapy.
